Cambridge Investment Research Advisors’s Inovio Pharmaceuticals INO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-1,635
| Closed | -$10K | – | 3359 |
|
|
2023
Q4 | $10K | Sell |
1,635
-73
| -4% | -$360 | ﹤0.01% | 3167 |
|
|
2023
Q3 | $8K | Sell |
1,708
-509
| -23% | -$2.81K | ﹤0.01% | 3119 |
|
|
2023
Q2 | $12K | Sell |
2,217
-1,742
| -44% | -$14K | ﹤0.01% | 3143 |
|
|
2023
Q1 | $39K | Buy |
3,959
+175
| +5% | +$2.98K | ﹤0.01% | 3064 |
|
|
2022
Q4 | $71K | Buy |
3,784
+469
| +14% | +$10.6K | ﹤0.01% | 2948 |
|
|
2022
Q3 | $69K | Buy |
3,315
+75
| +2% | +$1.92K | ﹤0.01% | 2911 |
|
|
2022
Q2 | $67K | Sell |
3,240
-2,407
| -43% | -$67.8K | ﹤0.01% | 2915 |
|
|
2022
Q1 | $243K | Buy |
5,647
+119
| +2% | +$5.36K | ﹤0.01% | 2723 |
|
|
2021
Q4 | $331K | Sell |
5,528
-1,592
| -22% | -$128K | ﹤0.01% | 2437 |
|
|
2021
Q3 | $612K | Sell |
7,120
-162
| -2% | -$16.3K | ﹤0.01% | 1890 |
|
|
2021
Q2 | $810K | Sell |
7,282
-813
| -10% | -$78.1K | ﹤0.01% | 1698 |
|
|
2021
Q1 | $901K | Buy |
8,095
+1,311
| +19% | +$172K | ﹤0.01% | 1499 |
|
|
2020
Q4 | $720K | Sell |
6,784
-653
| -9% | -$86.9K | ﹤0.01% | 1526 |
|
|
2020
Q3 | $1.03M | Buy |
7,437
+2,956
| +66% | +$616K | 0.01% | 1172 |
|
|
2020
Q2 | $1.45M | Buy |
4,481
+3,594
| +405% | +$577K | 0.01% | 920 |
|
|
2020
Q1 | $79K | Buy |
+887
| New | +$54.7K | ﹤0.01% | 2135 |
|
|
2019
Q4 | – | Sell |
-1,083
| Closed | -$27K | – | 2442 |
|
|
2019
Q3 | $27K | Buy |
1,083
+17
| +2% | +$517 | ﹤0.01% | 2314 |
|
|
2019
Q2 | $38K | Hold |
1,066
| – | – | ﹤0.01% | 2159 |
|
|
2019
Q1 | $48K | Buy |
1,066
+83
| +8% | +$4.18K | ﹤0.01% | 2229 |
|
|
2018
Q4 | $47K | Hold |
983
| – | – | ﹤0.01% | 2091 |
|
|
2018
Q3 | $66K | Buy |
983
+83
| +9% | +$4.62K | ﹤0.01% | 2174 |
|
|
2018
Q2 | $42K | Sell |
900
-83
| -8% | -$4.58K | ﹤0.01% | 2164 |
|
|
2018
Q1 | $56K | Buy |
983
+58
| +6% | +$3.14K | ﹤0.01% | 2096 |
|
|
2017
Q4 | $46K | Buy |
925
+90
| +11% | +$5.58K | ﹤0.01% | 2068 |
|
|
2017
Q3 | $63K | Sell |
835
-6
| -0.7% | -$446 | ﹤0.01% | 1944 |
|
|
2017
Q2 | $79K | Buy |
+841
| New | +$71.9K | ﹤0.01% | 1861 |
|
|
2014
Q4 | – | Sell |
-2,022
| Closed | -$239K | – | 1437 |
|
|
2014
Q3 | $239K | Buy |
+2,022
| New | +$252K | 0.01% | 1210 |
|
|
2014
Q2 | – | Sell |
-1,819
| Closed | -$291K | – | 1354 |
|
|
2014
Q1 | $291K | Sell |
1,819
-61
| -3% | -$8.76K | 0.01% | 977 |
|
|
2013
Q4 | $262K | Buy |
1,880
+353
| +23% | +$35.3K | 0.01% | 944 |
|
|
2013
Q3 | $152K | Buy |
+1,527
| New | +$128K | 0.01% | 1090 |
|
Other funds holding INO
SFI
GCP
HF
Cambridge Investment Research Advisors's INO Position: Q1 2024 in Review
Cambridge Investment Research Advisors sold out of Inovio Pharmaceuticals (INO) in Q1 2024, closing a stake of 1,635 shares — an estimated $10K sold.
Cambridge Investment Research Advisors first reported a position in INO in Q3 2013 and held it in 30 quarters. The position peaked at $1.45M in Q2 2020. 89 funds tracked by Wall St. Rank hold INO as of Q1 2024.
- Cambridge Investment Research Advisors reported no remaining Inovio Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
- Cambridge Investment Research Advisors sold 1,635 Inovio Pharmaceuticals shares in Q1 2024, an estimated $10K.
- Cambridge Investment Research Advisors first reported a position in Inovio Pharmaceuticals in Q3 2013 and held it in 30 quarters.
- Cambridge Investment Research Advisors's Inovio Pharmaceuticals position peaked at $1.45M in Q2 2020.
- 89 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q1 2024.
Based on Cambridge Investment Research Advisors's 13F filing for Q1 2024, filed 24 Apr 2024.